[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,070,512
  • Shares Outstanding, K 444,196
  • Annual Sales, $ 49,800 K
  • Annual Income, $ -50,340 K
  • EBIT $ -24 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.97
  • Price/Sales 20.60
  • Price/Cash Flow N/A
  • Price/Book 4.18

Options Overview Details

View History
  • Implied Volatility 139.61% (+33.18%)
  • Historical Volatility 80.69%
  • IV Percentile 37%
  • IV Rank 14.88%
  • IV High 421.18% on 02/09/26
  • IV Low 90.38% on 01/20/26
  • Expected Move (DTE 2) 0.09 (3.53%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 1,012
  • Volume Avg (30-Day) 872
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 35,284
  • Open Int (30-Day) 32,908
  • Expected Range 2.33 to 2.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 3
  • High Estimate $-0.05
  • Low Estimate $-0.06
  • Prior Year $0.01
  • Growth Rate Est. (year over year) -700.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.52 +58.55%
on 05/07/26
2.53 -4.74%
on 05/12/26
+0.69 (+40.12%)
since 04/10/26
3-Month
1.28 +88.28%
on 02/13/26
2.53 -4.74%
on 05/12/26
+1.10 (+83.97%)
since 02/12/26
52-Week
0.51 +369.15%
on 05/15/25
2.53 -4.74%
on 05/12/26
+1.74 (+257.62%)
since 05/12/25

Most Recent Stories

More News
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C....

LXRX : 2.41 (+4.33%)
Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter...

LXRX : 2.41 (+4.33%)
Lexicon: Q1 Earnings Snapshot

Lexicon: Q1 Earnings Snapshot

LXRX : 2.41 (+4.33%)
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

SONATA-HCM anticipated to be fully enrolled mid-2026  Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical...

LXRX : 2.41 (+4.33%)
Lexicon Pharmaceuticals: Whether the Pipeline Narrative Can Justify the Valuation

Barchart Research What to Expect from LXRX Earnings LXRX Generated May 6, 2026 Current Price $1.6000 EPS Estimate $$-0.04 Consensus Rating Moderate Buy Average Move 8.55% Lexicon Pharmaceuticals: Whether...

LXRX : 2.41 (+4.33%)
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC)...

LXRX : 2.41 (+4.33%)
HTGC : 15.98 (-0.44%)
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May...

LXRX : 2.41 (+4.33%)
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

 Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...

LXRX : 2.41 (+4.33%)
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.  (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College...

LXRX : 2.41 (+4.33%)
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential...

LXRX : 2.41 (+4.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 2.82
2nd Resistance Point 2.67
1st Resistance Point 2.54
Last Price 2.41
1st Support Level 2.27
2nd Support Level 2.12
3rd Support Level 1.99

See More

52-Week High 2.53
Last Price 2.41
Fibonacci 61.8% 1.76
Fibonacci 50% 1.52
Fibonacci 38.2% 1.28
52-Week Low 0.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.